Measurement and interpretation of pneumococcal IgG levels for clinical management

Clinical and Experimental Immunology

Volumn 133, Issue 3, 2003, Pages 364-369

  Balmer, P ^a   North, J ^b   Baxter, D ^c   Stanford, E ^a   Melegaro, A ^d   Kaczmarski, E B ^a   Miller, E ^d   Borrow, Ray ^a,e  

^a WITHINGTON HOSPITAL   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

IgG antibodies; Pneumococcal vaccination; Serotype specific assay

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; PNEUMOCOCCAL IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALGORITHM; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; CHILD; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFECTION PREVENTION; INFECTION SENSITIVITY; INTERMETHOD COMPARISON; MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; TREATMENT PLANNING; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; DISEASE SUSCEPTIBILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; PATIENT SELECTION; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SENSITIVITY AND SPECIFICITY; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 0041324979     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02232.x     Document Type: Article

References (18)

1. CDC Recommendations of the Advisory Committee on Immunization Practices (ACIP). Prevention of Pneumococcal Disease. MMWR 1997; 46:No. RR-8.
2. Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19:187-95.
3. CDC Recommendations of the Advisory Committee on Immunization Practices (ACIP). Preventing Pneumococcal Disease among infants and young children. MMWR 2000; 49:No. RR-9.
4. Chief Medical Officer, Chief Nursing Officer, Chief Pharmacist. Extending Meningitis C vaccine to 20-24 year olds; Pneumococcal vaccine for at-risk under 2 year olds. London: HMSO, 2000: PL/CMO/2002/1, PL/CNO/2002/1, PL/CPHO/2002/1.
5. Musher D, Chapman AJ, Goree A et al. Natural and vaccine related immunity to Streptococcus pneumoniae. J Infect Dis 1986; 154:245-56.
6. Musher DM, Watson DA, Baughin RE. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection? J Infect Dis 1990; 161:736-40.
7. Musher DM, Luchi MJ, Watson DA et al. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J Infect Dis 1990; 161:728-35.
8. Concepcion NF, Frasch CE. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme linked immunosorbent assay. Clin Diagn Laboratory Immunol 2001; 8:266-72.
9. George AC, Melegaro A. Invasive pneumococcal infection in England and Wales 1999. CDR Weekly 2001; 11:6-12.
10. Hazlewood M, Nusrat R, Kumararatne DS et al. The acquisition of anti-pneumococcal capsular polysaccharide, Haemophilus influenzae type b and tetanus toxoid antibodies, with age, in the UK. Clin Exp Immunol 1993; 93:157-64.
11. Koskela M. Serum antibodies to pneumococcal C polysaccharide in children: response to acute pneumococcal otitis media or to vaccination. Pediatr Infect Dis J 1987; 6:519-26.
12. Quataert SA, Kirsch C, Wiedl L et al. Assignment of weight based antibody units to human pneumococcal standard reference serum. Clin Diagn Laboratory Immunol 1995; 2:590-7.
13. Siber GR, Priehs C, Madore D. Standardization of antibody assays for measuring the response to pneumococcal infection and immunization. Pediatric Res 1989; 8:S84-S91.
14. Phipps DC, Strohmeyer S, Quataert S et al. Standardization of ELISA for the quantitation of antibodies to S. pneumoniae capsular polysaccharides (PnPs). Pediatric Res 1990; 27:179A.
15. Jodar L, Butler J, Carlone G et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003; 21:3265-72.
16. Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147:1100.
17. Sankilampi U, Honkanen PO, Bloigu A, Leinonen M. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1997; 179:1100-4.
18. Griffiths H, Lea J, Bunch C et al. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Imm 1992; 89:374-7.